Abstract
The cellular processing of three fluorescent N,N′-bis(aminoalkyl)-1,4-diaminoanthraquinones (aminoalkyl=2-aminoethyl, 3-aminoprop-1-yl or 4-aminobut-1-yl) and their dinuclear platinum complexes in A2780 human ovarian carcinoma cells with acquired resistance to cisplatin has been monitored over time by time-lapse fluorescence microscopy. The results were compared with the previously reported observations in the parent A2780 cell line. The cellular distribution pattern for the free ligands is similar in sensitive and resistant cells, whereas significant differences in cellular distribution were observed in the case of the platinum complexes. In the cisplatin-resistant cell line the platinum complexes were found to be sequestrated in acidic vesicles in the cytosol from the very beginning of the incubation. This sequestration was not observed in the case of sensitive cells. Platinum accumulation in vesicles possibly presents a mechanism of resistance to platinum complexes. This mechanism appears to be unrelated to the mechanism of deactivation of platinum compounds by glutathione. Encapsulation of the dinuclear platinum complexes in lysosomal vesicles provides a plausible explanation for the decreased activity of these compounds in the resistant cell line, as compared to the sensitive cell line.
Similar content being viewed by others
Abbreviations
- AQ2:
-
N,N′-bis(2-aminoethyl)-1,4-diaminoanthracene-9,10-dione
- AQ3:
-
N,N′-bis(3-aminoprop-1-yl)-1,4-diaminoanthracene-9,10-dione
- AQ4:
-
N,N′-bis(4-aminobut-1-yl)-1,4-diaminoanthracene-9,10-dione
- l-BSO:
-
l-buthionine-S,R-sulfoximine
- dien:
-
diethylenetriamine
- MTT:
-
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
- PAQ2:
-
[{trans-PtCl(NH3)2}2(μ-AQ2)](NO3)2
- PAQ3:
-
[{trans-PtCl(NH3)2}2(μ-AQ3)](NO3)2
- PAQ4:
-
[{trans-PtCl(NH3)2}2(μ-AQ4)](NO3)2
- PAM:
-
[{Pt(dien)}2(μ-AQ2)](NO3)4
- PBS:
-
phosphate buffered saline
References
Jansen BAJ, Wielaard P, Kalayda GV, Ferrari M, Molenaar C, Tanke HJ, Brouwer J, Reedijk J (2004) J Biol Inorg Chem 9:(accompanying paper)
Perez RP (1998) Eur J Cancer 34:1535–1542
Fuertes MA, Alonso C, Perez JM (2003) Chem Rev 103:645–662
Shen DW, Goldenberg S, Pastan I, Gottesman MM (2000) J Cell Physiol 183:108–116
Godwin AK, Meister A, Odwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) Proc Natl Acad Sci USA 89:3070–3074
Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS (1988) Science 241:1813–1815
Zhen WP, Link CJ, O’Connor PM, Reed E, Parker R, Howell SB, Bohr VA (1992) Mol Cell Biol 12:3689–3698
Chu G (1994) J Biol Chem 269:787–790
Johnson SW, Shen DW, Pastan I, Gottesman MM, Hamilton TC (1996) Exp Cell Res 226:133–139
Chaney SG, Sancar A (1996) J Natl Cancer Inst 88:1346–1360
Lowe SW, Ruley HE, Jacks T, Housman DE (1993) Cell 74:957–967
Moorehead RA, Singh G (2000) Biochem Pharmacol 59:337–345
Olivero OA, Semino C, Kassim A, Lopezlarraza DM, Poirier MC (1995) Mutat Res Lett 346:221–230
Molenaar C, Teuben JM, Heetebrij RJ, Tanke HJ, Reedijk J (2000) J Biol Inorg Chem 5:655–665
Watt GW, Cude WA (1968) Inorg Chem 7:335–338
Racoosin EL, Swanson JA (1993) J Cell Biol 121:1011–1020
Kim JH, Lingwood CA, Williams DB, Furuya W, Manolson MF, Grinstein S (1996) J Cell Biol 134:1387–1399
Kelland LR, Barnard CFJ, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, Harrap KR (1994) Cancer Res 54:5618–5622
Perez JM, Kelland LR, Montero EI, Boxall FE, Fuertes MA, Alonso C, Navarro-Ranninger C (2003) Mol Pharmacol 63:933–944
Perez JM, Montero EI, Quiroga AG, Fuertes MA, Alonso C, Navarro-Ranninger C (2001) Met-Based Drugs 8:29–37
Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR (1991) Br J Cancer 64:215–220
Mulder GJ, Ouwerkerk-Mahadevan S (1997) Chem-Biol Interact 105:17–34
Jansen BAJ, Brouwer J, Reedijk J (2002) J Inorg Biochem 89:197–202
Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, Kondo T (1995) Cancer Res 55:4297–4301
Timmer-Bosscha H, Mulder NH, de Vries EGE (1992) Br J Cancer 66:227–238
Oehlsen ME, Qu Y, Farrell N (2003) Inorg Chem 42:5498–5506
Aggarwal SK (1993) J Histochem Cytochem 41:1053–1073
Litterst CL (1984) Agents Actions 15:520–524
Bour-Dill C, Gramain MP, Merlin JL, Marchal S, Guillemin F (2000) Cytometry 39:16–25
Edwards PG, Kendall MD, Morris IW (1991) Scanning Microsc 5:797–810
Acknowledgements
The authors wish to thank Johnson Matthey (Reading, UK) for a generous gift of K2PtCl4. Also the support and sponsorship by COST Actions D20/0001/00, D20/0002/00 and D20/003/01 (biocoordination chemistry) is kindly acknowledged. This work has been performed under auspices of the joint BIOMAC Research Graduate School of Leiden University and Delft University of Technology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kalayda, G.V., Jansen, B.A.J., Molenaar, C. et al. Dinuclear platinum complexes with N,N′-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance. J Biol Inorg Chem 9, 414–422 (2004). https://doi.org/10.1007/s00775-004-0540-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-004-0540-5